Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled “If NIH Challenges Genzyme’s Patents, Does Anyone Care?” Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.
Related News
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 23, 2026
In the News
Daniel Farris Assesses Data Center Development in Wisconsin
Foley & Lardner LLP partner Daniel Farris is featured for his perspective on the trajectory of data center development in the Milwaukee Business Journal article, “Survey: Current pace of data center development is unsustainable."
April 22, 2026
In the News
Rebecca Bradley Shares Insights on AI Literacy Hopes for New Associates
Foley & Lardner LLP Chief Talent Officer Rebecca Bradley is featured in The American Lawyer article, "For Law Students, AI Literacy and Enthusiasm May Impact Big Law Employment Prospects,” offering perspective on how AI is factoring into expectations for incoming associates.